A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

An updated edition of the October 28, 2025, article. The global oncology market is entering a period of significant evolution, supported by rising cancer incidence and rapid scientific advancement.

According to DataM Intelligence, the global Breast Cancer Drugs Market reached USD 32.4 billion in 2024 and is projected to ...

Physicians stand to earn big money when signing up patients for drug trials. And lately, some of those trials have been ...

As clinical research evolves, disruptive trial designs are reshaping how oncology advances. By integrating novel ...

This is the first time scientists have shown that a common type of drug resistance in prostate cancer can be reversed, not ...

Researchers have discovered a key mechanism that makes prostate cancer cells resistant to the latest drugs, solving a ...

In early December 2025, Janux Therapeutics reported updated interim Phase 1 data for JANX007 in metastatic castration-resistant prostate cancer, showing anti-tumor activity with partial responses in ...

“In a hypothetical health plan covering 1 million lives, adding biosimilar denosumab to a health plan formulary may contribute to significant cost savings; savings can be reinvested to further expand ...

Janux posts what it called ‘positive trial data’ for its novel treatment in patients with late-stage prostate cancer.